Drug lookup
Drug reference

sisomicin

Aminoglycoside antibiotic · Antibiotic

Aminoglycoside antibioticAntibioticATC null
CDSCO approved
EXCRETION
not curated
INTERACTIONS
none in our sources
PREGNANCY
D
FDA category + note

Mechanism

Aminoglycosides are bactericidal antibiotics. They enter the bacterial cell via porin channels and an oxygen-dependent active transport process, then bind to ribosomal subunits, primarily 30S and 50S-30S interface. This binding freezes the initiation of protein synthesis, prevents polysome formation, and promotes disaggregation to monosomes. It also causes misreading of the mRNA code, leading to the production of abnormal or truncated proteins. The cidal action is also based on secondary changes in bacterial cell membrane integrity, leading to increased permeability and leakage, followed by cell death.

Indications

same purposes as gentamicincombined with penicillin for SABE

Dosing

Adult
3–5 mg/kg/day (interchangeable with gentamicin doses)
Renal adjustment
CLcr (ml/min) 70 -> 70% daily, 50 -> 50% daily, 30 -> 30% daily, 20–30 -> 80% alternate day, 10–20 -> 60% alternate day, <10 -> 40% alternate day

Pharmacokinetics

Half-life
2–4 hours (plasma)
Protein binding
clinically insignificant
Excretion
excreted unchanged in urine by glomerular filtration

Contraindications

  • pregnancy
  • perforated eardrum (ear drops)

Side effects

Common
ototoxicity (vestibular damage, cochlear damage)nephrotoxicity

Pregnancy & lactation

Pregnancy

D

Related guidelines

Other Aminoglycoside antibiotic drugs

Ask House about sisomicin

Continue into a citation-backed clinical answer with the drug context already attached.

Sources: KD Tripathi 7e·Verified: 2026-05-10 · House clinical team